ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement
ThermoGenesis Holdings, Inc. (NASDAQ: THMO) announced on January 11, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement. This follows a notification from Nasdaq on March 7, 2022, when the company was found to have fallen below the $1.00 minimum bid price for 30 consecutive business days. As of January 9, 2023, THMO's closing bid price has been at or above $1.00 for the previous 10 business days, thus closing the compliance matter.
- None.
- Non-compliance with Nasdaq's minimum bid price requirement prior to regaining compliance.
RANCHO CORDOVA, Calif., Jan. 11, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) ("Min Bid Price Rule").
On March 7, 2022, Nasdaq notified the Company that its common stock failed to maintain a minimum bid price of
On January 9, 2023, Nasdaq determined that for the last 10 consecutive business days, from December 22, 2022 to January 6, 2023, the closing bid price of the Company's common stock has been at
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this press release, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company, or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet FDA regulated requirements governing the Company's products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, risks associated with expanding into the Company's planned CDMO business, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in the Company's reports with the Securities and Exchange Commission ("SEC"), including, in particular, those set forth in the Company's Form 10-K for the year ended December 31, 2021.
Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:https://www.prnewswire.com/news-releases/thermogenesis-regains-compliance-with-nasdaq-minimum-bid-price-requirement-301718784.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
What does it mean for THMO to regain compliance with Nasdaq requirements?
When did ThermoGenesis receive notice of non-compliance from Nasdaq?
What was the minimum bid price for THMO to remain listed on Nasdaq?
What was the date when THMO regained compliance?
What stock symbol is associated with ThermoGenesis Holdings?
